Latest 8-K filings

Presurance Holdings, Inc. announced a significant increase in net income and improved combined ratio for the second quarter of 2026, driven by enhanced underwriting and claims management.

Boost Run Inc. announced robust second quarter 2026 financial results, featuring a 270% revenue increase to $31.1 million and a total contract value of $1.9 billion.

Proficient Auto Logistics has successfully completed the acquisition of Hansen & Adkins and concurrently priced a $75 million convertible note offering.

Bitmine Immersion Technologies announced dividend payment dates and amounts for its 9.50% Series A Perpetual Preferred Stock.

Star Equity Holdings announced Q2 2026 financial results, showing a 54.6% revenue increase but a widened net loss and decreased adjusted net income per share.

Safe Pro Group Inc. announced record Q2 2026 results with 1,336% revenue growth, driven by AI-powered threat detection solutions for U.S. government contracts, achieving 75% AI gross margins.

Vistagen Therapeutics announced fiscal Q1 FY27 financial results, highlighting revenue from an agreement expiration, reduced operating expenses, and a net loss, alongside mixed clinical data for fasedienol and a cash runway extending into 2027.

Cycurion, Inc. announced strong Q2 2026 results, beating revenue and EPS consensus, with a nearly five-fold increase in gross margin and a landmark $54.6 million contract.

Outlook Therapeutics, Inc. announced the pricing of its public offering of common stock and accompanying warrants, raising approximately $55 million.

Clene Inc. announced Q2 2026 results, highlighting progress towards an ALS drug NDA submission and providing an operating runway through late Q4 2026, alongside financial updates.

Provident Financial Services, Inc. released an investor presentation on August 14, 2026, detailing its financial health, strategic initiatives, and market position.

Crinetics Pharmaceuticals announces the expiration of the HSR Act waiting period for its acquisition by Vertex Pharmaceuticals, moving closer to deal closure.

Moleculin Biotech announced positive Q2 2026 financial results, highlighting significant progress in its pivotal MIRACLE trial for relapsed/refractory AML with Annamycin showing triple complete remission rates.

Nightfood Holdings announced significant board composition changes, the appointment of a new Chief Financial Officer, and the formation of standing board committees, signaling a strategic move towards enhanced corporate governance and a potential NASDAQ listing.

My Size, Inc. announced a 53% year-over-year revenue increase for Q2 2026, reaching $3.1 million, but also reported a widening net loss and declining gross margins.

Rank One Computing Corporation announced second-quarter 2026 revenue of $5.1 million, nearly doubling sequentially, with gross margins improving to 90% and R&D revenue up 41% year-over-year.

Climb Bio, Inc. reports that its collaborator, Beijing Mabworks Biotech Co., Ltd., has dosed the first patient in a Phase 2 clinical trial for immunoglobulin A nephropathy in China.

Our Bond, Inc. announced its CEO, Doron Kempel, will host a live webinar on August 14, 2026, to discuss company matters, with presentation slides furnished as an exhibit.

Wheeler Real Estate Investment Trust, Inc. announced the appointment of Jason F. Simone as its new Chief Financial Officer, effective August 10, 2026.

Space Exploration Technologies Corp. has finalized its acquisition of Anysphere, Inc., integrating the company as a wholly owned subsidiary.

Leatt Corporation reported a 1% revenue increase to $16.39 million for Q2 2026, with net income down 20% to $908,989, while year-to-date figures show a 14% revenue rise and 19% net income growth.

Quince Therapeutics reported Q2 2026 results, highlighting the acquisition of Orphai Therapeutics, a $115 million private placement, and advancements in its LAM-001 program for pulmonary diseases.

Professional Diversity Network, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in total revenues and an increased net loss, primarily due to amortization of acquired copyrights and reduced demand in key service areas.

Diversified Energy Company confirms preliminary discussions regarding a potential acquisition of Birch Resources, emphasizing its disciplined acquisition strategy.

Suncrete, Inc. announced a 146% year-over-year revenue increase for Q2 2026, reaching $97.2 million, while maintaining its full-year financial guidance despite a widened net loss.

Replimune Group announced FDA accelerated approval for TUDRIQEV in combination with nivolumab for advanced melanoma, alongside a $150 million financing to support commercial launch and clinical trials.

Aptevo Therapeutics announced second-quarter 2026 financial results and a business update, detailing strong clinical momentum for mipletamig in AML, a new Chief Scientific Officer, non-dilutive funding for APVO451, and a radiopharmaceutical collaboration with Niowave.

Delcath Systems, Inc. has updated its bylaws to designate exclusive forums for corporate and federal securities claims.

BIO-key International announced a 13% increase in Q2 revenues and a 51% reduction in net loss, driven by strong license fee growth and international contract wins.

Outlook Therapeutics announced third quarter fiscal year 2026 financial results and highlighted the FDA approval of LYTENAVA, positioning it for a U.S. launch with significant sales potential.